vs
Side-by-side financial comparison of GRID DYNAMICS HOLDINGS, INC. (GDYN) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
GRID DYNAMICS HOLDINGS, INC. is the larger business by last-quarter revenue ($104.1M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 3.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 12.0%).
Escape Dynamics, Inc. was a Colorado-based technology company that operated 2010–2015 focused on bringing to market single-stage-to-orbit reusable electromagnetically powered spaceplanes.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
GDYN vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.1M | $86.8M |
| Net Profit | $-1.5M | — |
| Gross Margin | 34.8% | 67.4% |
| Operating Margin | 61.7% | -84.7% |
| Net Margin | -1.4% | — |
| Revenue YoY | 3.7% | 17.7% |
| Net Profit YoY | -150.6% | — |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.1M | — | ||
| Q4 25 | $106.2M | $86.8M | ||
| Q3 25 | $104.2M | $67.5M | ||
| Q2 25 | $101.1M | $60.0M | ||
| Q1 25 | $100.4M | $49.3M | ||
| Q4 24 | $100.3M | $73.7M | ||
| Q3 24 | $87.4M | $58.6M | ||
| Q2 24 | $83.0M | $31.1M |
| Q1 26 | $-1.5M | — | ||
| Q4 25 | $306.0K | — | ||
| Q3 25 | $1.2M | $-91.3M | ||
| Q2 25 | $5.3M | $-111.7M | ||
| Q1 25 | $2.9M | $-116.2M | ||
| Q4 24 | $4.5M | — | ||
| Q3 24 | $4.3M | $-83.5M | ||
| Q2 24 | $-817.0K | $-97.1M |
| Q1 26 | 34.8% | — | ||
| Q4 25 | 34.0% | 67.4% | ||
| Q3 25 | 33.3% | 43.0% | ||
| Q2 25 | 34.1% | 5.5% | ||
| Q1 25 | 36.8% | -0.8% | ||
| Q4 24 | 36.9% | 68.7% | ||
| Q3 24 | 37.4% | 46.2% | ||
| Q2 24 | 35.6% | -0.8% |
| Q1 26 | 61.7% | — | ||
| Q4 25 | 0.5% | -84.7% | ||
| Q3 25 | -0.2% | -140.7% | ||
| Q2 25 | -0.1% | -189.8% | ||
| Q1 25 | -2.0% | -245.8% | ||
| Q4 24 | 1.3% | -117.5% | ||
| Q3 24 | 2.4% | -152.1% | ||
| Q2 24 | 0.0% | -327.6% |
| Q1 26 | -1.4% | — | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | 1.1% | -135.3% | ||
| Q2 25 | 5.2% | -186.2% | ||
| Q1 25 | 2.9% | -235.5% | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 4.9% | -142.7% | ||
| Q2 24 | -1.0% | -312.2% |
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.01 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.06 | $-0.33 | ||
| Q1 25 | $0.03 | $-0.36 | ||
| Q4 24 | $0.06 | $-0.24 | ||
| Q3 24 | $0.05 | $-0.28 | ||
| Q2 24 | $-0.01 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $327.5M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $530.1M | $698.6M |
| Total Assets | $605.0M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $327.5M | — | ||
| Q4 25 | $342.1M | $297.0M | ||
| Q3 25 | $338.6M | $300.8M | ||
| Q2 25 | $336.8M | $301.2M | ||
| Q1 25 | $325.5M | $359.7M | ||
| Q4 24 | $334.7M | $323.8M | ||
| Q3 24 | $231.3M | $397.5M | ||
| Q2 24 | $256.0M | $412.5M |
| Q1 26 | $530.1M | — | ||
| Q4 25 | $542.1M | $698.6M | ||
| Q3 25 | $537.7M | $702.3M | ||
| Q2 25 | $532.2M | $698.5M | ||
| Q1 25 | $517.4M | $767.9M | ||
| Q4 24 | $517.8M | $710.4M | ||
| Q3 24 | $400.2M | $773.5M | ||
| Q2 24 | $388.4M | $768.5M |
| Q1 26 | $605.0M | — | ||
| Q4 25 | $612.9M | $913.2M | ||
| Q3 25 | $613.2M | $904.9M | ||
| Q2 25 | $608.9M | $907.4M | ||
| Q1 25 | $590.9M | $966.7M | ||
| Q4 24 | $592.2M | $910.4M | ||
| Q3 24 | $477.3M | $991.1M | ||
| Q2 24 | $443.6M | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.9M | $-52.6M | ||
| Q3 25 | $7.0M | $-78.7M | ||
| Q2 25 | $14.4M | $-67.4M | ||
| Q1 25 | $9.4M | $-103.7M | ||
| Q4 24 | $7.1M | $-73.3M | ||
| Q3 24 | $9.2M | $-59.0M | ||
| Q2 24 | $10.7M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $6.1M | $-61.9M | ||
| Q3 25 | $2.9M | $-89.5M | ||
| Q2 25 | $10.2M | $-74.9M | ||
| Q1 25 | $6.0M | $-109.9M | ||
| Q4 24 | $4.4M | $-77.5M | ||
| Q3 24 | $5.9M | $-61.3M | ||
| Q2 24 | $8.0M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | -71.3% | ||
| Q3 25 | 2.8% | -132.7% | ||
| Q2 25 | 10.1% | -124.9% | ||
| Q1 25 | 6.0% | -222.8% | ||
| Q4 24 | 4.4% | -105.1% | ||
| Q3 24 | 6.8% | -104.6% | ||
| Q2 24 | 9.7% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 10.7% | ||
| Q3 25 | 3.9% | 16.1% | ||
| Q2 25 | 4.1% | 12.4% | ||
| Q1 25 | 3.3% | 12.6% | ||
| Q4 24 | 2.6% | 5.7% | ||
| Q3 24 | 3.7% | 3.9% | ||
| Q2 24 | 3.2% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 32.34× | — | ||
| Q3 25 | 5.92× | — | ||
| Q2 25 | 2.73× | — | ||
| Q1 25 | 3.21× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDYN
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
